Purpose: Various strategies have recently emerged to improve the diagnostic prediction of prostate cancer (CaP). One such strategy includes the mass profiling of serum protein fractions selectively adsorbed onto chemically modified probes. In the current study we further validated this approach, while offering a more versatile, less expensive and yet equally predictive alternative to existing technologies.
Prostate specific antigen (PSA) is the only clinically relevant serological marker for prostate cancer (CaP) in use today. 1 Unfortunately a myriad of pathological and normal states can induce increased serum PSA. 1 As a result, increased PSA correlates with pathologically confirmed CaP in only 30% of the patients biopsied, while false-negative rates also approach 30%. 2 For this reason a number of serological markers have been investigated. However, to date no distinct advantages over PSA have emerged. This is due in part to the high degree of pathological heterogeneity known to be associated with this disease. Therefore, the use of a group of markers correlating with a spectrum of pathological transformations may then be expected to determine more accurately the presence, aggressiveness and stage of CaP. 3 From this perspective in 1982 the term operational fingerprinting was coined by groups that used mass spectrometry combined with multivariate analysis to identify single cell organisms. 4, 5 More than 20 years later strategies involving the combination of innovative protein fractionation, mass analysis and statistical classification methodologies have emerged as useful tools for CaP detection. 6 -10 The mass analyzers most commonly used for this type of analysis are matrix assisted laser desorption ionization (MALDI) time of flight (Tof) mass spectrometry and a variation of this instrument, surface enhanced laser desorption-Tof. MALDI-Tof based instruments have been chosen for protein profiling due to a high tolerance for contamination inherent in complex biological solutions, while generating rather simple mass spectra primarily containing singly charged ions. 11, 12 In addition, these instruments often attain high attomole to low femptomole detection in the low (L) molecular weight (MW) range of 2 to 10 kDa. 11 As with the previously mentioned identification of microbes, sophisticated statistical algorithms such as neural networking, artificial intelligence and a technique denoted AdaBoost have proved necessary to define discriminatory spectral patterns for the detection of CaP from serum. 4, 6 -8, 10 This is primarily due to the considerable intraindividual and interindividual heterogeneity found throughout a population in conjunction with the complex mass spectra inherent with this approach. To date none of the serological proteins responsible for identifying CaP have been identified, which may be due in part to the fact that the surface enhanced laser desorption-Tof approach is greatly limited by the amount of protein captured on chip. Therefore, a scaleable technique that allows adequate isolation and, therefore, characterization of serum proteins is highly desirable.
We further validated this newly emergent strategy for CaP detection and developed improvements over existing technol-ogies. We optimized an extraction methodology that was found to enhance reproducibly the LMW protein fraction in a high throughput manner. 9, 12, 13 In addition, we used established multivariate statistical techniques to identify diagnostic peaks of interest used to predict CaP in a healthy group and in patients with local and metastatic disease. 14 The results of this study are reported with a highly encouraging outcome.
MATERIALS AND METHODS
Patient samples. All serological samples were obtained from patients between ages 45 and 83 in a 2-year period at our institution (table 1) . Of the 168 serological samples obtained for this study 98 were from healthy individuals and 70 were from patients with pathologically confirmed CaP. Of the CaP patients 52 had organ confined CaP and presented with Gleason score 6 -7 tumors, none had been treated at the time of blood draw and all had undetectable postoperative PSA. Of the 18 patients who presented with advanced (metastatic) disease 14 received no treatment prior to blood draw, while 4 were found retrospectively to have received treatment prior to this study.
Sample preparation. Serum samples were obtained by venous blood draw into gold top tubes, separated by centrifugation and stored at Ϫ80C. Exclusion criteria included extensive turbidity and extensive hemolysis. Turbidity was assessed visually. The level of hemolysis was determined by monitoring at 540 nm and/or by the presence of the hemoglobin ␣ and ␤ pair at 15.126 and 15.867 kDa, respectively. Serum was assayed for total protein content (DC kit, BioRad Laboratories, Hercules, California) and diluted to a concentration of 1 mg/ml in H 2 O. Protein extraction was performed by adding 90 l diluted serum to 10 l 10% (volume per volume) trifluoroacetic acid (TFA) and 10 l activated Corasil Bondapak C18 solid core 37 to 50 resin (Waters, Millford, Massachusetts) in a 0.5 ml polypropylene centrifuge tube, mixing for 2 minutes at room temperature and pelleting by centrifugation. The resin was washed twice in 100 l 1% TFA. Extraction was done with 25 l 50:50 acetonitrile (CH 3 CN):1% (volume per volume) TFA while shaking for 1 minute, and the addition of 25 l of 100% CH 3 CN and shaking for 1 additional minute.
Mass analysis. All data were obtained using the Ciphergen Protein Biosystem II with delayed extraction in conjunction with Ciphergen 2.1 version software (Ciphergen, Fremont, California). Freshly prepared protein extracts were immediately mixed 1:1 with 50% saturated matrix consisting of sinapic acid (Fluka, Saint Louis, Missouri) in 50:50 CH 3 CN:1% TFA. The dried droplet method was used to crystallize 1 l of the matrix/sample mixture on a blank sample gold probe (Ciphergen). The mass window was set to acquire data from 0 to 20 kDa with 600 nanosecond delayed extraction time. Each mass final spectrum consisted of an average of 200 optimal shots. Patient serum was extracted and analyzed in triplicate and averaged prior to statistical analysis. Any sample that presented with a portion of the triplicate spectra that exhibited error above 35% was re-analyzed. The intensity of the ultraviolet nitrogen laser (337 nm) was set at 240 V and the filter average was set to 0.2 times the expected peak width with baseline smooth set to 25 points before baseline correction. On the day of the experiment external calibration was done with protein standards, namely [Mϩ1] ϩ and [Mϩ2] 2ϩ peaks from each standard, bovine insulin (5733.6), bovine ubiquitin (8564.8) and bovine cytochrome C (12230.9). Internal calibration was also completed with a combination of external protein standards and C18 extracted serum proteins to mark proteins found in each patient sample that encompassed the MW range of interest.
Reproducibility. To assess the instrumental error in analysis we randomly selected, extracted and profiled a single sample on 5 consecutive spots on a chip. Experimental error was calculated by extracting 1 sample 5 separate times and an estimate of population error was calculated for 5 separate samples from the normal group. To determine the semiquantitative limitations of these conditions we calculated the relative SD of standardized intensities throughout the spectrum. Average instrumental error was 15.7%, experimental error was 18.3% and estimated population error was 24.1%.
Post-acquisition data processing. We used all of the postsmoothed and normalized raw data points that made up the entire mass spectrum. The entire spectrum from 2 to 13.5 kDa consisted of more than 7,760 points, an average of 1 point per 1 to 3 mass units, which increased with mass proportional to the instruments resolution. Thus, the average protein peak translated to 5 to 10 points. This approach has the potential to pick up otherwise overlooked shoulders on peaks and small but significant peaks potentially missed by some peak detection algorithms. The resultant raw data files for each spectrum were imported into Peakfit 4.0 (SPSS, Inc., Chicago, Illinois) for further data processing. This included reducing the data to a mass window of 2 to 13.5 kDa, smoothing with a Gaussian convolute algorithm, background correcting with a second derivative zero technique, normalizing to 1.0 and zeroing of negative data. This file was then exported, lined up and processed in the statistical analysis step, as described.
Each Peakfit file was then exported as a text file and up loaded back into an Excel (Microsoft, Redmond, Washington) spreadsheet to line up all spectra according to a single MW ϫ axis almost equal to the mass accuracy of the internally calibrated spectra. The resulting data matrix was further transformed or standardized, such that all data were set between 0 and 1.0 by taking the difference between each sample intensity (S X ) and the lowest intensity within a group (S L ) for the range (S H Ϫ S L ) using the equation 15 This technique places equal emphasis on all signal intensities, whether high or low, and can be especially useful when minimally and highly expressed proteins are found to be important for diagnosis.
Optimizing the training set using multivariate analysis. The training set was first analyzed by calculating the relative class separation matrices from the standardized data matrix containing all protein spectra, as previously described. 14, 15 Weight values were then calculated for each MW value and sorted according to the highest statistical relevance between the predetermined patient groups CaP and normal. The weight value (W) is a statistically derived function that approaches significance as the distance between the means () for each group increases and the SD () decreases using the formula, W ϭ ( 1 Ϫ 2 )/( 1 ϩ 2 ). 14, 15 In this way the most significant protein peaks were then used as the top weighted data points (m/z intensities). Top weighted data points, which maximally differentiated individuals with CaP from healthy individuals, were obtained from the combined set of 48 mass spectra (18 patients with CaP and 30 healthy indi- . † Gleason grade 6 -7 tumors and no treatment before blood draw. ‡ Four patients were actively being treated with androgen ablation therapy at blood draw and all others provided blood before therapy. viduals), randomly pulled from the original set of 168 spectra and unblinded. A series of data sets containing from the top 10 to the top 7,760 data points were further analyzed with multivariate analysis as a means of determining the optimal number of top weighted points required to completely separate the spectra of patients with CaP from those of healthy subjects. K-means and hierarchical cluster analysis (HCA) were done on Euclidean distance matrices formed from the standardized data matrix using SPSS 10 (SPSS, Inc.) or Statistica 6.0 (StatSoft, Inc., Tulsa, Oklahoma). 15 The Ward method was used as the amalgamation rule for HCA. The data set with the least number of misclustered patient serum samples was then used as the diagnostic standard. This data was then re-plotted using multidimensional scaling to visualize the final training set in 3 dimensions. The final 36 peak intensities were further analyzed by Cluster and TreeView analysis freeware (Michael Eisen, Standford University, Stanford, California), in which relative intensities are increased or decreased relative to the mean. All protein peaks found to be CaP specific by statistical analysis were quality control checked visually in Origin 6.0 (OriginLab Corp., Northampton, Massachusetts) to determine that high weighted data points were in fact real and not artifacts associated with noise or other unforeseen factors.
Class prediction by weighted voting scheme was performed as previously described on blinded spectra using the optimized training set as the diagnostic standard. 14 The optimized training set was also tested along with the unknowns but separately by compiling the entire standardized data matrix minus the sample being tested (n Ϫ 1), thus, allowing each of the known samples to be treated as an unknown through a technique known as n-way cross validation. 14 The weighted voting scheme approach forces each data point within a test spectrum to cast a vote, which is dependent on the similarity to 1 or another patient group. The similarity between any data point from an unknown patient to either group was measured as the distance between the decision boundary (halfway between the class means) and the intensity of that data point. A diagnosis was determined by tallying all votes belonging to any 1 group. However, if the sum of votes for 1 group is only slightly larger than another, the class prediction is considered less reliable. 14 To measure the significance of a diagnosis prediction strength must be calculated. Low prediction strength would then be considered an unreliable diagnosis, resulting in an outcome of nonprediction, otherwise referred to as nondiagnosed.
RESULTS
Optimized protein extraction methodology. Although generally not noted in publications of this type, hemolysis is a serious problem that leads to the release of a number of LMW proteins from red blood cells that are not easily resolved ( fig.  1 ). Techniques that claim to avoid this problem rely primarily on the extraction of hemoglobin by iron chelating resins that leave hundreds of other contaminants behind. Therefore, hemolyzed serum samples, as determined spectrophotometrically, were excluded from our analysis. In addition, to avoid degradation issues we also avoided the use of any samples stored for more than 2 years at Ϫ80C or those that were thawed more than twice. We have found that beyond this time samples begin to form a number of degradation peaks in the LMW field (unpublished data).
Our optimized, solid core C18 extraction approach was found to enhance greatly the LMW lipophilic protein fraction ( fig. 2) . The removal of common, high abundance proteins such as albumin, which constitutes about 70% of the total protein, has historically proved to be quite challenging. Generally speaking LMW proteins/peptides are not soluble under aqueous conditions in noncomplexed form, as is found in the high acid, high salt conditions used in the current study, while more abundant high (H) MW proteins such as albumin are not soluble under high organic conditions. Therefore, this strategy selectively enhances lipophilic proteins, encompassing most LMW growth factors and cytokines, while allowing HMW proteins such as albumin and the Igs to be washed away. In addition, the high organic extraction process limits the solubilization of residual albumin and other HMW hydrophilic proteins. To maximize further the limit of detection (LOD) we also focused our attention toward the low mass range below 15 kDa because instruments of this type have an inverse correlation between sensitivity and MW ( fig. 2, c) . The LOD for this instrument under the described conditions was found to approach high attomole to low femptomole concentrations. In anticipation for adaptating this approach to future scale-up experiments and high throughput analysis addition we compared other extraction mediums to the Corasil Bondapak resin used in this study. A 300 Extended-C18 5 m solid core bulk resin (Agilent Technologies, Palo Alto, California), a variety of prepacked extraction spin cartridges (Nest Group, Southborough, Massachusetts) and 96-well prepacked plates (Alltech, Nicholasville, Kentucky) were found to yield comparable results (data not shown).
Identification of diagnostic peaks. Hierarchical and K-means cluster analysis were performed on the highest weighted peaks generated from the training set containing spectra from 48 patient samples. Each data set contained a lesser number of top weighted data points from the whole spectra containing 7,760 points down to 10 points. The maximal number of misclustered patient spectra using any 1 multivariate analysis technique was plotted vs the top weighted data points to determine the optimal number of points required to differentiate maximally these 2 groups ( fig. 3, a) . This resulted in the generation of an optimized training set across 280 data points (corresponding to 36 protein peaks after the inspection of each peak in Origin 6.0) with complete separation between the CaP and healthy groups (table 2). Interestingly of the protein peaks identified in this study minimal overlap with m/z values obtained from previously published reports were found (table 2). 6 -8, 10 To visualize better the separation between CaP and healthy individuals we used multidimensional scaling to transform these data into visually comprehensible and spatially relevant 3-dimensional depictions of the similarities and dissimilarities between each patient spectrum. 15 The final configuration demonstrated a stress value of 0.007, denoting an acceptable distortion of transformed data below 0.15 ( fig. 3, b) . The combination of these common statistical approaches represents a powerful tool for discriminating diagnostic protein peaks following MALDI-Tof mass analysis of complex proteins from serum ( fig. 3, b) .
The final 36 peak intensities derived from the top 280 m/z values were further analyzed by Cluster and TreeView analysis with the relative intensities shown to be increased or decreased relative to the mean ( fig. 4 ). This approach visualizes the relative levels of all pertinent proteins per patient, while clarifying which proteins may be differentially regulated to a greater extent over a population, as is the case for the m/z value 2,935. To ensure that those peaks identified with statistical analysis were real and not the result of some unforeseen anomaly all 36 peaks found to be differentially expressed by statistical analysis were further determined to be present by re-graphing tightly clustered subgroups within each patient group ( fig. 5 ). In figure 5 the 4 proteins with an m/z value of 2,935, 5,913, 9,129 and 9,420, respectively, were picked based on the high relative abundance and relative differences for 5 different patient samples that tightly subclustered within a specific patient group.
Testing diagnostic efficiency. The diagnostic efficiency of the FIG. 3 . Identifying diagnostic peaks. a, training set containing 48 serum samples from 30 healthy subjects and 18 patients with local CaP was randomly selected from entire set of 169 samples and temporarily unblinded. Total of 7,760 data points making up each spectrum from 2 to 13.5 kDa were aligned in order of top to least weighted and analyzed by k-means and hierarchical clustering analysis. Number of misclustered patient samples was plotted against number of highest weighted data points to quantify optimal number of points necessary for complete separation between CaP and normal. In this case 280 data points making up 38 distinct protein peaks represented highest diagnostic accuracy from training set. b, multidimensional scaling was used to assess visually separation between mass spectra from healthy subjects (NL) and patients with CaP in final training set containing 48 patient spectra. optimized m/z values obtained from the training set was tested using class prediction by a weighted voting scheme, as discussed. With this approach a set of blinded unknowns was compared with clinical standards (in this case the top 280 m/z values) to arrive at a diagnosis. Unknown patient spectra were then analyzed against the corresponding top weighted points in the training set and ranked according to a weighted voting scheme. Use of the top weighted 280 data points (36 peaks) yielded 1 false-positive results, 4 false-negative results and 5 nonpredictions of the 168 samples tested. This corresponded to 94.1% sensitivity and 99.0% specificity for differentiating the CaP and normal groups (table 3) .
Separation among all 168 individuals was further visualized by hierarchical clustering analysis ( fig. 6 ). This analysis was based on the portion of the spectra that correlated with the top 280 data points (36 protein peaks). The healthy group clustered tightly to the right, while the CaP group clustered tightly to the left. Most patients with metastatic disease clustered tightly together within the organ confined CaP group. Two patients with metastatic disease who clustered within the normal group were also considered to represent false-negative results by class validation. These 2 patients had stable or decreasing PSA at the time of blood draw as a direct result of treatment with Casodex (AstraZeneca, Wilmington, Delaware) and orchiectomy in 1 each. No clinically relevant reason was identified to help explain the other misclustered individuals, including 2 healthy subjects and 2 patients with organ confined CaP. Multivariate analysis was performed on mass spectra acquired from serum samples representing a 48 patient training set. This type of analysis was completed with standard statistical software packages such as Statistica 6.0 or SPSS 10, thereby, identifying an optimized set of top weighted m/z values (protein peaks) capable of accurately diagnosing CaP in a blinded test set containing 168 patient serum samples. This approach yielded 94.1% sensitivity and 99.0% specificity with 1 false-positive, 4 false-negative and 5 nondiagnosable individuals. It may be expected that a higher rate of falsepositive findings would be identified since statistically about 6% of the individuals in a general population in this age group would be expected to have CaP. 1 However, the lack of false-positive results identified in this study was likely due to the extensive pre-screening done in this group of individuals. Of the individuals included in the healthy group 23 presented with PSA increased above 4.0 ng/ml and/or benign prostatic hyperplasia and prostatitis. In agreement with our mass analysis results all of these patients were confirmed to have negative results by biopsy. In addition, our set of subjects included 8 patients who presented with a suspicious nodule on digital rectal examination in conjunction with a PSA below 4.0 ng/ml and who were also confirmed by biopsy to have CaP. All of these patients were found to have positive test results in our test. Of the 70 patients with CaP tested 18 were found to have metastatic disease. This population was found to cluster tightly together as a subgroup within patients with CaP. This indicates that there are likely serological changes specific to metastatic disease worthy of further investigation. In addition, this set of subjects was retrospectively found to include 4 patients who had recently been treated with androgen ablation therapy. Two of these patients clustered within the healthy group by HCA and they were also interestingly considered to represent false-negative findings by class validation analysis. This observation suggests that a future application of this methodology may be to follow response rates to androgen ablation therapy, which can result in decreased PSA but not necessarily in decreased CaP growth or regression in advanced disease.
As mentioned, recent variations of this approach have been reported for CaP detection with similar successes. 6 -8, 10 One such study used an immobilized metal affinity chromatography (IMAC) affinity approach, in which metal binding proteins were used for CaP detection, while a second study used the H4 Ciphergen C16 modified chip in a fashion similar to our own. While each of these approaches had outcomes of relatively high diagnostic accuracy, comparison of the reported m/z values (protein peaks) shows a considerable lack of overlap (table 2) . From this perspective only 3 of the 36 protein peaks identified in this study with m/z values of 2,066, 2,366 and 9,129, respectively, overlapped (by Ϯ15 atomic units) with the 31 separate peaks (below 20 kDa) from previously reported studies (table 2) . This lack of correlation is not entirely surprising, considering that a number of dif- 6 . Multivariate analysis. All 168 patient spectra were combined and analyzed by hierarchical clustering analysis using top weighted protein peaks to discern CaP from normal. Of 70 patients with local (red) and metastatic (black) CaP 65 tightly clustered in 1 arm at left. Of 98 normal healthy subjects (blue) 96 were clustered tightly at right. Only 2 healthy subjects were clustered in CaP group, while 2 patients with metastatic and 3 with local CaP were clustered in healthy group. ferences exist in the extraction techniques and statistical methods used in each of these studies. In fact, the IMAC approach was used by the same group that reported 2 other studies with almost completely different sets of protein peaks, likely as a result of the different statistical approaches used in these studies (table 2) . 7, 8 On the other hand, there was a high level of correlation for the 2 collaborating studies using similar approaches (table 2) . 8, 10 Interestingly in one of the latest studies results indicate that diagnostic accuracy can be increased by combining mass profiles from 2 protein chips (IMAC and strong cationic exchange) as opposed to 1 chip. This observation seems to agree with studies in which different strategies were used with almost equal outcomes and yet different m/z peaks. However, sensitivity and specificity were generally lower in the study mentioned than in 2 previous studies in which the IMAC chip was used alone. 4, 7, 9 In this respect in future experiments careful comparison among studies using the same extraction techniques and statistical analysis may undoubtedly prove important. In addition, it may be important to address the possibility of intra-institutional and interinstitutional variances in sample acquisition and handling. Taken together these studies demonstrate that altered abundances of a great number of proteins/peptides likely exist in the serum which, when combined, are unique to the presence of CaP.
With the potential of this emerging mass profiling technique becoming more apparent it is important that a validation process continues as these proteins are characterized and further studied. Our approach was shown to be as effective as that in previous reports, while it used inexpensive commercially available software applications. In addition, we chose a C18 modified resin as opposed to, for example the H4 chip, which generated richer, sharper spectra attainable in a high throughput manner on any MALDI-Tof at a considerable decrease in cost compared to protein chip methodologies. While protein chips are sensible for samples of limited protein concentration, this approach is not necessary for samples such as serum. In addition, there are an unlimited number of spherical, high surface area resins of various chemistries that are appropriate for protein fractionation in multiple dimensions. In our ongoing research this approach has also allowed for scaling up for the purpose of protein characterization, which we have complemented with multidimensional protein identification technologies in conjunction with 1 and 2-dimensional electrophoresis. 16 -19 Upon further characterization of these markers we hope to gain a better understanding of their biological role, while developing enzyme-linked immunosorbent based arrays, thus, allowing a more quantitative approach for the diagnosis and subclassification of CaP. The potential uses of these applications are extensive and should enable the identification of markers for malignancies other than CaP and a wide variety of other diseases.
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